Probi Probiotic Shown To Reduce Inflammation During Acute Stress

Probi's probiotic "significantly decreased" plasma levels of two inflammatory markers coupled to acute stress in study, with the firm planning further research into the gut-brain axis.

Headache
• Source: Shutterstock

Sweden’s Probi AB is to further research the gut-brain axis after a study showed its probiotic strain reduced the release of two inflammatory markers coupled to acute stress.

Intake of Probi’s patented probiotic strain Lactiplantibacillus plantarum HEAL9 (LPHEAL9) for four weeks by subjects with chronic stress exposed to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Ingredients & Safety

AESGP Annual Meeting: Harmonizing EU VMS Max Levels Could Cost Sector Over €200m

 
• By 

Limited capacity and a two-to-three year timescale for reformulation could mean that many VMS supplements disappear from the market, warns EPPA partner Alexandra Bocquillion, speaking at the AESGP Annual Meeting in Warsaw, Poland.

EU Pharma Reform: Council Proposes Rx Exemption For Topical Antimicrobials

 
• By 

The EU Council has introduced a key amendment to Article 51 (para 1, point e) of the new pharma directive: “A medicinal product shall be subject to medical prescription where it is an antimicrobial, unless intended for topical use.”

Review Suggests Advantage Of Bayer’s Iberogast Advance For Digestive Disorders

 
• By 

Bayer's Iberogast Advance's combination of six herbal ingredients may produce a synergistic effect that acts on multiple underlying issues contributing to digestive disorders like functional dyspepsia (FD) and irritable bowel syndrome (IBS), a recently published study suggests.

Allergy Ingredient Itch Warning, ACNU Final Rule Scratch Extent Of FDA Authority For Label Changes

 

Effective date for ACNU OTC switch final rule and finding of severe itching from long-term use of common allergy ingredients are bookends for limits of FDA’s authority for product label changes.

More from HBW Insight

IBA Names Ooka Interim CEO; P&G, Sally Beauty Appoint Board Members – Appointments Roundup

The Independent Beauty Association announces CEO Don Frey will retire July 1 and will be replaced as interim CEO by Akemi Ooka, VP of global supply chain and sustainability resources.

Navamedic Adds OTC Naloxone With DNE Pharma Acquisition

 
• By 

Norway's Navamedic will move into the addiction treatment market with the acquisition of DNE Pharma, adding to its portfolio an OTC opioid overdose reversal spray.

Kenvue’s Latest Tylenol Brand Launch Steers Consumers To Dietary Supplement Section

 

The firm doesn’t hold back on linking Muscle & Joint turmeric and tamarind formulation and Muscle & Joint + Stress also containing sceletium extract to the Tylenol brand while also pointing out that neither formulation contains acetaminophen